Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:AVRO

AVROBIO - AVRO Stock Forecast, Price & News

$0.87
-0.03 (-3.33%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.86
$0.93
50-Day Range
$0.58
$0.90
52-Week Range
$0.56
$4.29
Volume
671,791 shs
Average Volume
493,931 shs
Market Capitalization
$38.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.29

AVROBIO MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
506.1% Upside
$5.29 Price Target
Short Interest
Healthy
0.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of AVROBIO in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.18) to ($1.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

500th out of 1,040 stocks

Biological Products, Except Diagnostic Industry

83rd out of 175 stocks

AVRO stock logo

About AVROBIO (NASDAQ:AVRO) Stock

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Stock News Headlines

See how to make money instead of spending it on Black Friday with this offer
Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Even the world’s richest billionaires are investing in the tiny company behind it. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday.
See how to make money instead of spending it on Black Friday with this offer
Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Even the world’s richest billionaires are investing in the tiny company behind it. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday.
Avrobio, Inc. (NASDAQ: AVRO)
See More Headlines
Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Company Calendar

Last Earnings
11/08/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVRO
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.29
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+506.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-119,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.88 per share

Miscellaneous

Free Float
40,972,000
Market Cap
$38.18 million
Optionable
Not Optionable
Beta
1.58

Key Executives

  • Mr. Geoff MacKay BSc (Age 56)
    Co- Founder, Pres, CEO & Director
    Comp: $754.39k
  • Mr. Erik John Ostrowski M.B.A. (Age 49)
    CFO & Treasurer
    Comp: $554.66k
  • Mr. Jeffrey Medin Ph.D.
    Scientific Founder
  • Mr. Matthew Arnold
    Head of Operations
  • Mr. Steven N. Avruch J.D. (Age 61)
    Chief Legal Officer & Sec.
  • Ms. Monique Da Silva
    Sr. VP of Corp. Communications
  • Ms. Deanna M. Petersen MBA (Age 60)
    Chief Bus. Officer
  • Ms. Azadeh Golipour Ph.D.
    Chief Technology Officer
  • Mr. Andreas Kouri
    Sr. VP of Global Supply Chain & External Manufacturing
  • Dr. Essra Ridha FFPM
    M.D., Chief Medical Officer













AVRO Stock - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVRO shares.
View AVRO analyst ratings
or view top-rated stocks.

What is AVROBIO's stock price forecast for 2023?

6 Wall Street research analysts have issued 1 year target prices for AVROBIO's shares. Their AVRO share price forecasts range from $3.00 to $8.00. On average, they predict the company's stock price to reach $5.29 in the next twelve months. This suggests a possible upside of 506.1% from the stock's current price.
View analysts price targets for AVRO
or view top-rated stocks among Wall Street analysts.

How have AVRO shares performed in 2022?

AVROBIO's stock was trading at $3.85 at the start of the year. Since then, AVRO shares have decreased by 77.3% and is now trading at $0.8721.
View the best growth stocks for 2022 here
.

Are investors shorting AVROBIO?

AVROBIO saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 252,500 shares, a decline of 17.6% from the October 31st total of 306,300 shares. Based on an average daily trading volume, of 299,200 shares, the short-interest ratio is presently 0.8 days. Currently, 0.7% of the shares of the stock are sold short.
View AVROBIO's Short Interest
.

When is AVROBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our AVRO earnings forecast
.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) announced its earnings results on Tuesday, November, 8th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.02.

What other stocks do shareholders of AVROBIO own?
When did AVROBIO IPO?

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.79%), Vanguard Group Inc. (2.64%), Citadel Advisors LLC (1.17%), Two Sigma Investments LP (0.90%), Two Sigma Advisers LP (0.90%) and SVB Wealth LLC (0.65%). Insiders that own company stock include Christopher Paige, Geoffrey Mackay and Philip J Vickers.
View institutional ownership trends
.

How do I buy shares of AVROBIO?

Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $0.87.

How much money does AVROBIO make?

AVROBIO (NASDAQ:AVRO) has a market capitalization of $38.18 million. The company earns $-119,130,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis.

How many employees does AVROBIO have?

The company employs 122 workers across the globe.

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The official website for the company is www.avrobio.com. The company can be reached via phone at (617) 914-8420 or via email at ir@ampliphibio.com.

This page (NASDAQ:AVRO) was last updated on 11/28/2022 by MarketBeat.com Staff